Balboa Wealth Partners’s DexCom DXCM Stock Holding History

Balboa Wealth Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,516	Closed	-$210K	–	314
2024 Q1	$210K	Buy	+1,516	New	+$191K	0.06%	224

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Balboa Wealth Partners's DXCM Position: Q2 2024 in Review

Balboa Wealth Partners sold out of DexCom (DXCM) in Q2 2024, closing a stake of 1,516 shares — an estimated $210K sold.

Balboa Wealth Partners first reported a position in DXCM in Q1 2024 and held it in 1 quarter. The position peaked at $210K in Q1 2024. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Balboa Wealth Partners reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Balboa Wealth Partners sold 1,516 DexCom shares in Q2 2024, an estimated $210K.
Balboa Wealth Partners first reported a position in DexCom in Q1 2024 and held it in 1 quarter.
Balboa Wealth Partners's DexCom position peaked at $210K in Q1 2024.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Balboa Wealth Partners's 13F filing for Q2 2024, filed 13 Aug 2024.